Report: Drug companies should spend more on R&D

06/12/2007 | Financial Times (free content)

A PricewaterhouseCoopers report urges pharmaceutical firms to shift more of their spending from marketing to research because the industry's current business model "is both economically unsustainable and operationally incapable" of moving quickly to produce new treatments demanded by global markets. The report also predicts the emergence of a single global regulatory system by 2020.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD